TY - JOUR. T1 - Suppressive effect of locally produced interleukin-10 on respiratory syncytial virus infection. AU - Ruan, Yan. AU - Okamoto, Yoshitaka. AU - Matsuzaki, Zensei. AU - Endo, Shuichiro. AU - Matsuoka, Tomokazu. AU - Kohno, Tadashi. AU - Chazono, Hideaki. AU - Eiko, Ito. AU - Tsubota, Kazuo. AU - Saito, Ichiro. PY - 2001. Y1 - 2001. N2 - Interleukin (IL)-10 is known to be a multifunctional cytokine. This study was designed to evaluate the role of IL-10 during respiratory syncytial virus (RSV) infection using a C57BL/6 transgenic (TG) mouse model in which the expression of murine IL-10 cDNA was regulated by a human salivary amylase promoter (IL-10 TG mice). These mice expressed a large amount of IL-10 in the nasal mucosa and in salivary glands. Viral replication in the respiratory tract after intranasal infection with RSV was suppressed significantly in IL-10 TG mice compared to non-transgenic controls. This suppression was IL-10 specific, because it was prevented by treating mice ...
Define respiratory syncytial virus immune globulin intravenous. respiratory syncytial virus immune globulin intravenous synonyms, respiratory syncytial virus immune globulin intravenous pronunciation, respiratory syncytial virus immune globulin intravenous translation, English dictionary definition of respiratory syncytial virus immune globulin intravenous. n. 1. Any of a class of proteins that are widespread in blood plasma, milk, muscle, and plant seeds and that are insoluble in pure water but soluble in...
Respiratory syncytial virus is one of the most important causes of respiratory tract infection in infants and the elderly worldwide. Transmitted by direct and indirect contact, respiratory syncytial virus spreads as readily in the hospital as it does in the community, making healthcare-associated infection common. Respiratory syncytial virus is a major preventable healthcare-associated infection with frequent outbreaks that can lead to high mortality rates in healthcare facilities. Proper infection prevention measures, including hand hygiene, standard and contact precautions, cohorting, and rapid diagnostic techniques, are critical in controlling the spread of respiratory syncytial virus in healthcare facilities and establishing a culture of patient and employee safety. Timely implementation of standard infection control measures will minimize its medical and economic impact.. ...
Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and vaccines against human Respiratory Syncytial Virus are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the Respiratory Syncytial Virus fusion protein or a neutralizing epitope of the G protein.
TY - JOUR. T1 - The secreted g protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement. AU - Bukreyev, Alexander. AU - Yang, Lijuan. AU - Collins, Peter L.. PY - 2012/10/1. Y1 - 2012/10/1. N2 - The respiratory syncytial virus (RSV) G and F glycoproteins are the neutralization antigens, and G also is expressed in a soluble form (sG). Previously, sG was demonstrated to reduce the efficiency of RSV antibody-mediated neutralization by serving as an antigen decoy and to inhibit the antibody-mediated antiviral effects of Fc receptor-bearing leukocytes. The present study demonstrated that effective antibody-mediated restriction in vivo, and the evasion of this restriction by sG, involves pulmonary macrophages and complement, but not neutrophils.. AB - The respiratory syncytial virus (RSV) G and F glycoproteins are the neutralization antigens, and G also is expressed in a soluble form (sG). Previously, sG was demonstrated ...
TY - JOUR. T1 - Respiratory Syncytial Virus-Induced Activation and Migration of Respiratory Dendritic Cells and Subsequent Antigen Presentation in the Lung-Draining Lymph Node. AU - Lukens, Michaël. AU - Kruijsen, Debby. AU - Coenjaerts, Frank E. J.. AU - Kimpen, Jan L. L.. AU - van Bleek, Grada M.. PY - 2009/7/15. Y1 - 2009/7/15. N2 - In the respiratory tract, different dendritic cell (DC) populations guard a tight balance between tolerance and immunity to infectious or harmless materials to which the airways are continuously exposed. For infectious and noninfectious antigens administered via different routes, different subsets of DC might contribute during the induction of T-cell tolerance and immunity. We studied the impact of primary respiratory syncytial virus (RSV) infection on respiratory DC composition in C57BL/6 mice. We also tracked the migration of respiratory DC to the lymph nodes and studied antigen presentation by lung-derived and lymph node-resident DC to CD4(+) and CD8(+) T ...
article{1942045, abstract = {Despite the medical importance of respiratory syncytial virus (RSV) infections, there is no vaccine or therapeutic agent available. Prophylactic administration of palivizumab, a humanized monoclonal RSV fusion (F) protein-specific antibody, can protect high-risk children. Previously, we have demonstrated that RSV can be neutralized by picomolar concentrations of a camelid immunoglobulin single-variable domain that binds the RSV protein F (F-VHHb nanobodies). Here, we investigated the mechanism by which these nanobodies neutralize RSV and tested their antiviral activity in vivo. We demonstrate that bivalent RSV F-specific nanobodies neutralize RSV infection by inhibiting fusion without affecting viral attachment. The ability of RSV F-specific nanobodies to protect against RSV infection was investigated in vivo. Intranasal administration of bivalent RSV F-specific nanobodies protected BALB/c mice from RSV infection, and associated pulmonary inflammation. Moreover, ...
Cell-surface viral proteins most frequently enter the cell through clathrin or caveolae endocytosis. Respiratory syncytial virus antigen internalization by immune cells is via caveolin, however, uptake of paramyxovirus cell membrane proteins by non-immune cells is done through clathrin-coated pits. In this work, the uptake of respiratory syncytial virus cell surface glycoproteins by non-immune human epithelial cells was investigated through indirect immunofluorescence with polyclonal anti-RSV antibody and confocal lasser-scanner microscopy. Clathrin and caveolae internalization pathways were monitored through specific inhibitors monodansylcadaverine (MDC) and methyl-beta-cyclodextrin (MBCD), respectively. Internalization of RSV antigens was inhibited by MDC but not by MBCD, implying that clathrin-mediated endocytosis is the major uptake route of RSV antigens by an epithelial human cell line.
Summary Intergenic and flanking gene regions for the 1C-1B, 1B-N, N-P, M-1A, G-F and F-22K gene junctions of respiratory syncytial virus strain 18537, representing antigenic subgroup B, were determined by dideoxynucleotide sequencing of polycistronic cDNAs and mRNAs. Comparison with their counterparts from the subgroup A strain A2 showed that the intergenic sequences were not conserved within or between the strains. Flanking non-coding gene sequences also were generally not conserved except for the highly conserved gene-start and gene-end transcription signals. The sequence of the overlap between the 22K and L genes was conserved almost exactly between the two subgroups.
Levine, S., Peeples, M. and Hamilton, R. The effect of respiratory syncytial virus infection on HeLa-cell macromolecular synthesis.. J. Gen. Virol. Vol. 37, no. OCT. (January 1977.): 53-63.. Peeples, M.E.. Studies on the polypeptide structure, the metabolic requirements for maturation, and persistence of respiratory syncytial (RS) virus in HeLa cell culture. Doctoral Dissertation. (January 1978.): -.. Peeples, M. and Levine, S.. Respiratory syncytial virus polypeptides: their location in the virion. Virology. Vol. 95, no. 1. (January 1979.): 137-145.. Peeples, M. and Levine, S.. Metabolic requirements for the maturation of respiratory syncytial (RS) virus. J. Gen. Virol. Vol. 50, no. SEP. (January 1980.): 81-88.. Peeples, M.E. and Levine, S.. Characteristics of a persistent respiratory syncytial virus infection in HeLa cells.. Virology. Vol. 113, no. 1. (January 1981.): 141-149.. Peeples, M.E. and Bratt, M.A. UV irradiation analysis of complementation between, and replication of, ...
Title: Prevention of Respiratory Syncytial Virus: A Review. VOLUME: 5 ISSUE: 1. Author(s):Emilio Palumbo. Affiliation:Department of Pediatric, Via DellArcangelo Michele 4, 71100, Foggia, Italy.. Keywords:Prevention, palivuzumab, motavizumab, VRS. Abstract: Antibodies mediate humoral immune responses and play key roles in the defense of viral infection by the recognition, neutralization, and elimination of viruses from the circulation. For the prevention of respiratory syncytial virus (RSV) infection, the pooled human plasma has been harvested and successfully developed as a prophylactic polyclonal RSV hyperimmune globulin, RespiGam (RSV-IGIV; MedImmune, Gaithersburg, MD). The success of RSV-IGIV validated the immunoprophylaxis approach for RSV prevention and led to the development of Synagis (palivizumab; MedImmune, Gaithersburg, MD), a humanized monoclonal antibody (mAb) that binds to the RSV F protein. Palivizumab is a potent anti-RSV mAb that is about 50-fold more potent than RSV-IGIV, and ...
Several broad categories of patients are most vulnerable to RSV infection. These include:. premature infants and all infants less than 1 year of age, children 2 years old with cardiac disease or chronic lung disease (for example, asthma, cystic fibrosis, etc.), those of any age with a compromised immune system, and those 65 years of age or older. Is respiratory syncytial virus (RSV) contagious? Respiratory syncytial virus (RSV) is contagious. In the United States, its the most common cause of inflammation of the small airways in the lungs (bronchiolitis) and of pneumonia in children under 1 year of age. It also is significant cause of respiratory illnesses in older adults. Nearly all children in the U.S. will have been infected by RSV by 2 years of age. RSV usually causes a mild respiratory infection, but it can occasionally cause more serious infections that require hospitalization from breathing compromise with bronchiolitis or pneumonia. RSV was discovered in 1956 (isolated from a chimpanzee ...
TY - JOUR. T1 - Interleukin-1-inhibitor activity induced by respiratory syncytial virus. T2 - Abrogation of virus-specific and alternate human lymphocyte proliferative responses. AU - Salkind, A. R.. AU - McCarthy, D. O.. AU - Nichols, J. E.. AU - Domurat, F. M.. AU - Walsh, E. E.. AU - Roberts, N. J.. PY - 1991/1/1. Y1 - 1991/1/1. N2 - Respiratory syncytial virus (RSV) infection has been shown to induce human mononuclear leukocyte (MNL) production of net interleukin-1 (IL-1)-inhibitor activity. In the current studies of IL-1-inhibitor effects, RSV-exposed cells were compared with autologous MNL that were sham-exposed or exposed to inactivated RSV or influenza virus (which induces net IL-1 activity and commonly elicits effective homotypic immunity). Exposure of MNL to influenza virus or inactivated RSV resulted in increased expression of human leukocyte antigen-DR, the IL-2 receptor, and the transferrin receptor and increased progression through the cell cycle by 3 days. In contrast, exposure to ...
The worldwide respiratory syncytial virus diagnostics market is poised to grow at a CAGR exceeding 10% over the forecast period (2016 to 2024). RSV Diagnostics Market stood at USD 625 million in 2015. High prevalence of neonatal infections & viral diseases and the need for early RSV detection mechanisms for infants are key drivers of this industry. Respiratory syncytial virus harms the respiratory tract, the immune system, the heart, and lungs; thus leading to serious illnesses. It mainly affects infants in the age group of 0 to 11 months.. However, there are instances of people above the age of 60 years being afflicted by this virus. This is essentially because of weak immunity. Some patients may even need hospitalization. Clinical symptoms of the RSV infection can seldom be distinguished from the symptoms of other respiratory disorders. Hence, there is a pressing need to develop precise & accurate diagnostic solutions for such a disease.. Browse Details of Report @ ...
The worldwide respiratory syncytial virus diagnostics market is poised to grow at a CAGR exceeding 10% over the forecast period (2016 to 2024). RSV Diagnostics Market stood at USD 625 million in 2015. High prevalence of neonatal infections & viral diseases and the need for early RSV detection mechanisms for infants are key drivers of this industry. Respiratory syncytial virus harms the respiratory tract, the immune system, the heart, and lungs; thus leading to serious illnesses. It mainly affects infants in the age group of 0 to 11 months.. However, there are instances of people above the age of 60 years being afflicted by this virus. This is essentially because of weak immunity. Some patients may even need hospitalization. Clinical symptoms of the RSV infection can seldom be distinguished from the symptoms of other respiratory disorders. Hence, there is a pressing need to develop precise & accurate diagnostic solutions for such a disease.. Browse Details of Report @ ...
The worldwide respiratory syncytial virus diagnostics market is poised to grow at a CAGR exceeding 10% over the forecast period (2016 to 2024). RSV Diagnostics Market stood at USD 625 million in 2015. High prevalence of neonatal infections & viral diseases and the need for early RSV detection mechanisms for infants are key drivers of this industry. Respiratory syncytial virus harms the respiratory tract, the immune system, the heart, and lungs; thus leading to serious illnesses. It mainly affects infants in the age group of 0 to 11 months.. However, there are instances of people above the age of 60 years being afflicted by this virus. This is essentially because of weak immunity. Some patients may even need hospitalization. Clinical symptoms of the RSV infection can seldom be distinguished from the symptoms of other respiratory disorders. Hence, there is a pressing need to develop precise & accurate diagnostic solutions for such a disease.. Browse Details of Report @ ...
The worldwide respiratory syncytial virus diagnostics market is poised to grow at a CAGR exceeding 10% over the forecast period (2016 to 2024). RSV Diagnostics Market stood at USD 625 million in 2015. High prevalence of neonatal infections & viral diseases and the need for early RSV detection mechanisms for infants are key drivers of this industry. Respiratory syncytial virus harms the respiratory tract, the immune system, the heart, and lungs; thus leading to serious illnesses. It mainly affects infants in the age group of 0 to 11 months.. However, there are instances of people above the age of 60 years being afflicted by this virus. This is essentially because of weak immunity. Some patients may even need hospitalization. Clinical symptoms of the RSV infection can seldom be distinguished from the symptoms of other respiratory disorders. Hence, there is a pressing need to develop precise & accurate diagnostic solutions for such a disease.. Browse Details of Report @ ...
TY - JOUR. T1 - The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. AU - Dakhama, Azzeddine. AU - Park, Jung Won. AU - Taube, Christian. AU - Joetham, Anthony. AU - Balhorn, Annette. AU - Miyahara, Nobuaki. AU - Takeda, Katsuyuki. AU - Gelfand, Erwin W.. PY - 2005/8/1. Y1 - 2005/8/1. N2 - Respiratory syncytial virus (RSV) infection in early life is suspected to play a role in the development of postbronchiolitis wheezing and asthma. Reinfection is common at all ages, but factors that determine the development of altered airway function after reinfection are not well understood. This study was conducted in a mouse model to define the role of age in determining the consequences on airway function after reinfection. Mice were infected shortly after birth or at weaning and were reinfected 5 wk later, followed by assessment of airway function, airway inflammation, ...
Respiratory syncytial virus strains (subgroup A) isolated from around the world during the period 1988-1991 were analysed to determine their relatedness. Analysis was by restriction mapping and nucleotide sequencing following amplification of selected regions of the virus genome by polymerase chain reaction (PCR). Twenty-three viruses of subgroup A isolated from cities in temperate regions of the Northern and Southern hemispheres and the tropics during the period 1988-1991 fell into distinct groupings closely related to four of the six lineages defined in analysis of recurrent epidemics within the same city (Birmingham, UK) during the same period. These observations confirm that multiple lineages of RS virus co-circulate locally, and show that very similar viruses are present simultaneously in widely separated countries.. ...
We have previously shown that respiratory syncytial virus (RSV) assembly occurs within regions of the host-cell surface membrane that are enriched in the protein caveolin-1 (cav-1). In this report, we have employed immunofluorescence microscopy to further examine the RSV assembly process. Our results show that RSV matures at regions of the cell surface that, in addition to cav-1, are enriched in the lipid-raft ganglioside GM1. Furthermore, a comparison of mock-infected and RSV-infected cells by confocal microscopy revealed a significant change in the cellular distribution of phosphocaveolin-1 (pcav-1). In mock-infected cells, pcav-1 was located at regions of the cell that interact with the extracellular matrix, termed focal adhesions (FA). In contrast, RSV-infected cells showed both a decrease in the levels of pcav-1 associated with FA and the appearance of pcav-1-containing cytoplasmic vesicles, the latter being absent in mock-infected cells. These cytoplasmic vesicles were clearly visible between 9
Human respiratory syncytial virus (RSV) is the main viral cause of respiratory tract infection in infants as well as some elderly and high-risk adults with chronic pulmonary disease and the severely immunocompromised. So far, no specific anti-RSV therapeutics or effective anti-RSV vaccines have been reported. Only one humanized monoclonal antibody, Palivizumab, has been approved for use in high-risk infants to prevent RSV infection. Ribavirin is the only drug licensed for therapy of RSV infection, but its clinical use is limited by its nonspecific anti-RSV activity, toxic effect, and relatively high cost. Therefore, development of novel effective anti-RSV therapeutics is urgently needed. The RSV envelope glycoprotein F plays an important role in RSV fusion with, and entry into, the host cell and, consequently, serves as an attractive target for developing RSV entry inhibitors. This article reviews advances made in studies of the structure and function of the F protein and the development of RSV entry
Clinical trial for Respiratory syncytial virus , A Study to Evaluate the Safety Reactogenicity and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age
Hela cells were used for culture of the virus. After 2 hours,when respir atory syncytial virus(RSV)attacked the celll,the remained medium was abandoned.The eagle medium with herb of Shuang Huang Lian oral liquid was put in every bottle of the test groups.The time of culture was 7 days. The results showed that Shuang Huang Lian oral liquid has distinct effect of antiRSV as compared with the control groups.
1KWE: Structure-antigenicity relationship studies of the central conserved region of human respiratory syncytial virus protein G.
Human respiratory syncytial virus is a medium-sized (120-200 nm) enveloped virus that contains a linear negative-sense RNA genome (must be converted to a positive RNA prior to translation). The former contains virally encoded F, G, and SH lipoproteins. The F and G lipoproteins are the only two that target the cell membrane, and are highly conserved among RSV isolates. HRSV is divided into two antigenic subgroups, A and B, on the basis of the reactivity of the virus with monoclonal antibodies against the attachment (G) and fusion (F)[6] glycoproteins. Subtype B is characterized as the asymptomatic strains of the virus that the majority of the population experiences. The more severe clinical illnesses involve subtype A strains, which tend to predominate in most outbreaks. Four of the viral genes code for intracellular proteins that are involved in genome transcription, replication, and particle budding, namely N (nucleoprotein), P (phosphoprotein), M (matrix protein), and L (large protein, ...
The respiratory syncytial virus (RSV) fusion glycoprotein (F) can interact with the small intracellular GTPase RhoA, and peptides derived from RhoA inhibit RSV replication. These observations initially suggested that RhoA-derived peptides might inhibit RSV replication by disrupting an in vivo interaction between RSV F and RhoA. However, recent data indicate that the antiviral activity of RhoA-derived peptides is not due to competitive inhibition of an hypothesized F-RhoA interaction, but is rather a function of the peptides intrinsic biophysical properties. We summarize here what is known about the mechanism of RSV inhibition by these peptides and give our opinion regarding the potential implications of this work with regards to RSV biology, and to the development of antiviral agents targeting RSV and other enveloped viruses.. ...
Bronchiolitis is caused by respiratory syncytial virus. Respiratory syncytial virus can be detected by identifying of the respiratory syncytial virus antigen in the nasal aspirates or identifying the respiratory syncytial virus specific antibody.
Respiratory syncytial virus (RSV) is the most important viral respiratory pathogen in children. Infection due to RSV represents a large public health burden; in Canada, it accounts for 5,800 hospitalizations annually. The peak incidence of RSV disease occurs between 2-6 months of age with half of all infants infected in the first year of life. Palivizumab has been approved for the prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high-risk of RSV disease. These children include those born premature, those with bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD).. With the recent approval of palivizumab in Canada, access to this medication has increased. However, there are limited data on utilization, compliance, and health outcomes, particularly the frequency and severity of RSV infections. The primary objective of this study is to provide insight into the current management (utilization, ...
Respiratory syncytial virus (RSV) is an enveloped virus that assembles into filamentous virus particles on the surface of infected cells. Morphogenesis of RSV is dependent upon cholesterol-rich (lipid raft) membrane microdomains, but the specific role of individual raft molecules in RSV assembly is not well defined. Here we show that RSV morphogenesis occurs within caveolar membranes and that both caveolin-1 and cavin-1, the two major structural and functional components of caveolae, are actively recruited to and incorporated into the RSV envelope. The recruitment of caveolae occurred just prior to the initiation of RSV filament assembly, and was dependent upon an intact actin network as well as a direct physical interaction between caveolin-1 and the viral G protein. Moreover, cavin-1 protein levels were significantly increased in RSV-infected cells, leading to a virus-induced change in the stoichiometry and biophysical properties of the caveolar coat complex. Our data indicate that RSV ...
Anti-Respiratory Syncytial Virus G Glycoprotein antibody [RSV133] (ab94966) has been cited in 2 publications. Find out more about the references
Respiratory syncytial virus (RSV) infection remains an important medical problem for infants and the elderly. Infection requires the fusion of the vira membrane...
Respiratory Syncytial Virus (RSV) is a contagious viral disease that is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under one year of age in the United States. Almost all children will have had an RSV infection by their second birthday. Of the infants and children exposed to RSV for the first time, 25 to 40 percent of them have signs or symptoms of bronchiolitis or pneumonia. However, only 0.5 to 2 percent will actually require hospitalization. Most children that do require hospitalization are under six months of age.. Premature infants, children under two years of age who have congenital heart or chronic lung disease, or children with a weakened immune system are at highest risk for developing severe disease. People of any age can develop an infection from RSV. However, when infections occur later in life, it is less severe. Adults at high risk for developing severe RSV disease include the elderly, adults with chronic heart or ...
Respiratory syncytial virus (RSV) is the leading cause of hospitalization especially in young children with respiratory tract infections (RTI). Patterns of circulating RSV genotypes can provide a better understanding of the molecular epidemiology of RSV infection. We retrospectively analyzed the genetic diversity of RSV infection in hospitalized children with acute RTI admitted to University Hospital Heidelberg/Germany between October 2012 and April 2013. Nasopharyngeal aspirates (NPA) were routinely obtained in 240 children younger than 2 years of age who presented with clinical symptoms of upper or lower RTI. We analyzed NPAs via PCR and sequence analysis of the second variable region of the RSV G gene coding for the attachment glycoprotein. We obtained medical records reviewing routine clinical data. RSV was detected in 134/240 children. In RSV-positive patients the most common diagnosis was bronchitis/bronchiolitis (75.4%). The mean duration of hospitalization was longer in RSV-positive compared to
Author Summary Respiratory syncytial virus (RSV) is a leading cause of pediatric lower respiratory tract disease. RSV has two IFN-I antagonist proteins, NS1 and NS2. In this study, we infected primary human dendritic cells with recombinant RSV from which the NS1 and/or the NS2 genes were deleted, and evaluated effects on the proliferation of autologous T lymphocytes during co-culture in vitro. We found that NS1, but not NS2, has a suppressive effect on two cell populations, namely CD103+ CD8+ T cells and Th17 cells, which are known to protect against viral respiratory infections, and a stimulatory effect on Th2 cells, which are involved in enhanced disease caused by RSV. We also provide evidence that these effects are not due to suppressed IFN-I production or signaling in dendritic cells or T cells, and that they likely result from reduced maturation of dendritic cells caused by the NS1 protein.
Respiratory syncytial virus (RSV) is a common respiratory pathogen that can cause severe pneumonia. In vivo studies of RSV can be difficult due to variation in viral infection and disease severity in some animal models. Factors that may contribute to the variation are decreases in viral titer due to preparation and storage and method of virus administration. Nebulization is one method of RSV administration that provides even distribution of virus to all lung lobes; however, the exact quantity of the virus killed by nebulization is not defined. To test the hypothesis that sucrose enhances RSV stability and infectivity, a series of in vitro experiments were conducted with RSV strain Memphis 37 stored at varying concentrations (0%, 3%, 5%, 8%, 10%, 15%, and 20%) of sucrose as a possible cryo- and nebulization protectant. The optimal in vitro concentration was then assessed in vivo in a lamb model. Prior to titering the virus on HEp-2 cells, the various virus solutions were subjected to one freeze-thaw
Respiratory syncytial virus (RSV) is the most frequent cause of bronchiolitis in infants and children worldwide. Many animal models are used to study RSV, but most studies investigate disease in adult animals which does not address the unique physiology and immunology that makes infants more susceptible. The perinatal (preterm and term) lamb is a useful model of infant RSV disease as lambs have similar pulmonary structure including airway branching, Clara and type II cells, submucosal glands and Duox/lactoperoxidase (LPO) oxidative system, and prenatal alveologenesis. Lambs can be born preterm (90% gestation) and survive for experimentation although both preterm and term lambs are susceptible to ovine, bovine and human strains of RSV and develop clinical symptoms including fever, tachypnea, and malaise as well as mild to moderate gross and histologic lesions including bronchiolitis with epithelial injury, neutrophil infiltration and syncytial cell formation. RSV disease in preterm lambs is more severe
Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
Respiratory Syncytial Virus is the leading cause of severe respiratory illnesses such as bronchiolitis and pneumonia in young children. RSV is a paramyxovirus with negative-sense genomic RNA that encodes for eleven proteins, two of which, F and G are major surface proteins. In the present study, we synthesized and used various nanoparticles with and without capping agents to study the inhibition of RSV infection in human cell lines. We used silver, gold and chitosan nanoparticles. Nanoparticles were conjugated to various proteins, DNA as well as poly lactic acid, to study the inhibition of RSV infection in human cell lines. The characteristics of nanoparticles were evaluated by SEM (scanning electron microscopy), TEM (transmission electron microscopy, and EAD analysis. Cell cytotoxicity of each of the nanoparticle was established and the effectiveness of RSV inhibition was evaluated by microscopic examination for syncytia formation and by immunofluorescence microscopy. Our preliminary results revealed
Respiratory Syncytial Virus (RSV) Fusion Protein antibody [681] for ELISA, ICC/IF. Anti-Respiratory Syncytial Virus (RSV) Fusion Protein mAb (GTX39259) is tested in Respiratory Syncytial Virus samples. 100% Ab-Assurance.
(2004) Arnold et al. Virology. Respiratory syncytial virus (RSV) is worldwide the single most important respiratory pathogen in infancy and early childhood. The G glycoprotein of RSV, named attachment protein, is produced by RSV-infected lung epithelial cells in both a membrane-anchored (mG prote...
Nasal swabs offer a sensitive sampling method for the detection of respiratory viruses in children. Respiratory syncytial virus (RSV) is an exception and it is detected more often in nasopharyngeal aspirates (NPA) than in nasal swabs when it is searched for using immunoassays or viral culture.1 2 Therefore, more laborious and painful NPA have been the first-choice specimen for high-yield recovery of RSV by conventional methods. We wanted to examine whether the use of reverse transcription-polymerase chain reaction (RT-PCR) increases the usefulness of nasal swabs by comparing the performance of nasal swab-RT-PCR with NPA-immunoassays in the detection of RSV infections in children.. We studied 112 children ...
The respiratory syncytial virus (RSV) is a human pathogen that causes a lower respiratory infection in infants and healthy adults. The first incidence of RSV was recorded in the 1960s. The greatest success against viruses has always been by increasing immunity through vaccination like in smallpox, measles, influenza, polio. Though RSV spread its roots almost six decades ago, the creation of a vaccine against RSV is still an ongoing challenge. The structural proteins of RSV, mainly F and G, play an essential role in pathogenicity. Structural instability of the F protein is responsible for making the vaccine discovery an uncertain outcome. This review focuses on the details of the vaccine strategies that have been explored so far. It includes an emphasis on the initial formalin-inactivated vaccine, structure-based vaccine, monoclonal antibodies like Palivizumab with a concise portrayal of nanoparticle, chimeric vaccines, and maternal derived immunization. The structure-based vaccine is one of the most
Respiratory Syncytial Virus Clinical Information: RSV infection can cause a variety of respiratory illnesses. Infants with a lower respiratory tract infection typically have a runny nose and a decrease in appetite before any other symptoms appear...
Respiratory syncytial virus (RSV) causes respiratory tract infections and is a major cause of lower respiratory tract infection and hospital visits during infancy and childhood. For premature infants and infants with congenital heart disease there is a prophylactic medication. During winter months in temperate climates there is an annual epidemic. Infection in tropical climates is most common during the rainy season. 60% of infants, in the United States, are infected during their first RSV season, and nearly all children will have been infected by the age of 2-3 years of age. 2-3% of those infected develop bronchiolitis which required hospitalization. Infection does provide immunity, although, it wanes over time allowing for people to be infected multiple times. It is a negative-sense, single-stranded RNA virus of the family Paramyxoviridae which can cause measles and mumps. The name comes from the fact that F proteins on the surface of the virus cause the cell membranes on nearby cells to ...
Respiratory syncytial virus is highly contagious. It spreads through droplets containing the virus when someone coughs or sneezes. It also can live on surfaces (like counters or doorknobs) and on hands and clothing. So people can get it if they touch something thats contaminated.. RSV can spread quickly through schools and childcare centers. Babies often get it when older kids carry the virus home from school and pass it to them. Almost all kids have had RSV at least once by the time theyre 2 years old.. RSV infections often happen in epidemics that last from late fall through early spring. Respiratory illness caused by RSV - such as bronchiolitis or pneumonia - usually lasts about a week, but some cases may last several weeks.. ...
Chu, H., Tielsch, J., Katz, J., Magaret, A., Khatry, S., LeClerq, S., Shrestha, L., Kuypers, J., Steinhoff, M., & Englund, J. (2017). Transplacental Transfer of Maternal Respiratory Syncytial Virus (RSV) Antibody and Protection Against RSV Disease in Infants in Rural Nepal.. Journal of Clinical Virology : The Official Publication of the Pan American Society for Clinical Virology, 95 (). http://dx.doi.org/10.1016/j.jcv.2017.08.017 ...
Human RSV IgA ELISA kit is intended for determining in-vitro quantitative levels of human IgA antibodies against respiratory syncytial virus (RSV) in serum or
|strong|Mouse anti Respiratory syncitial virus, major surface glycoprotein G antibody, clone 8C5|/strong| recognizes the major glycoprotein G of Respiratory Syncytial virus (RSV). RSV is a 100-350 nm …
An experimental vaccine to protect against respiratory syncytial virus (RSV), a leading cause of illness and hospitalization among very young children, elicited high levels of RSV-specific antibodies when tested in animals, according to a report in the journal Science.
Respiratory syncytial virus enters the body through the eyes, nose or mouth. It spreads easily through the air on infected respiratory droplets. You or your child can become infected if someone with RSV coughs or sneezes near you. The virus also passes to others through direct contact, such as shaking hands.. The virus can live for hours on hard objects such as countertops, crib rails and toys. Touch your mouth, nose or eyes after touching a contaminated object and youre likely to pick up the virus.. An infected person is most contagious during the first week or so after infection. But in infants and those with weakened immunity, the virus may continue to spread even after symptoms go away, for up to four weeks. ...